Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 18
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 17
Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
Khine Shan, Shivani Dalal, Nyein Nyein Thaw Dar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 849-849
Open Access | Times Cited: 11
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113587-113587
Open Access | Times Cited: 9
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
Francesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4943-4956
Open Access | Times Cited: 6
FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
Yuanli Zhen, Kai Liu, Lei Shi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Taroh Satoh, Philippe Barthélémy, Lucia Nogová, et al.
European Journal of Cancer (2025), pp. 115262-115262
Closed Access
Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
Yazhou Wang, Yihong Zhang, Jinxin Liu, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3886-3899
Closed Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116845-116845
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Molecular signatures of intrahepatic Cholangiocarcinoma: Role in targeted therapy selection
Tetiana Glushko, James Costello, Ranjit S. Chima, et al.
European Journal of Radiology (2025), pp. 112056-112056
Closed Access
The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
Mario Romeo, Marcello Dallio, Filadelfo Nardo, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 4, pp. 124-124
Open Access
Matrix gla protein mediates CD8+ T-cell exhaustion to facilitate immune evasion in intrahepatic cholangiocarcinoma
Xiaohan Cao, Stephan Lang, Yulei Xie, et al.
CytoJournal (2025) Vol. 22, pp. 41-41
Open Access
Mitochondria targeted drug delivery system overcoming drug resistance in intrahepatic cholangiocarcinoma by reprogramming lipid metabolism
Yi Duan, Mengqiong Deng, Bin Liu, et al.
Biomaterials (2024) Vol. 309, pp. 122609-122609
Closed Access | Times Cited: 3
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets
Vindhya Vijay, Negin Karisani, Lei Shi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 3
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling
Lipika Goyal, Daniel DiToro, Antoine Hollebecque, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 3
Multi-omics-driven discovery of invasive patterns and treatment strategies in CA19-9 positive intrahepatic cholangiocarcinoma
Delin Ma, Pengcheng Wei, Hengkang Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma
Love Goyal, Daniel DiToro, Francesco Facchinetti, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 2
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2181-2192
Closed Access | Times Cited: 1
A case of treatment-resistant advanced gastric cancer with FGFR2 gene alteration successfully treated with pemigatinib
Ryo Shinomiya, Yasushi Sato, Takanori Yoshimoto, et al.
International Cancer Conference Journal (2024) Vol. 13, Iss. 3, pp. 240-244
Closed Access | Times Cited: 1
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
Satoshi Kawano, Megumi Ikemori Kawada, Sayo Fukushima, et al.
Anticancer Research (2024) Vol. 44, Iss. 6, pp. 2393-2406
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top